# Efficacy and Tolerability of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis

> **NCT03069144** · PHASE1,PHASE2 · COMPLETED · sponsor: **Haus Bioceuticals** · enrollment: 28 (actual)

## Conditions studied

- Psoriasis
- Psoriasis Vulgaris

## Interventions

- **DRUG:** HAT1 topical solution
- **DRUG:** Calcipotriol

## Key facts

- **NCT ID:** NCT03069144
- **Lead sponsor:** Haus Bioceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01-06
- **Primary completion:** 2012-04-11
- **Final completion:** 2012-05-28
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2017-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03069144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03069144, "Efficacy and Tolerability of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03069144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*